ETHICANN PHARMACEUTICALS AWARDED 1st IN IMPACT TRACK COMPETITION AT BEND VENTURE CONFERENCE OCT. twenty first
Pharmaceuticals

ETHICANN PHARMACEUTICALS AWARDED 1st IN IMPACT TRACK COMPETITION AT BEND VENTURE CONFERENCE OCT. twenty first

Ethicann Prescribed drugs is an Rising World Chief Growing Excessive Worth Cannabinoid-Based mostly Moral Drug Therapies reformulating authorised medicine into oral dissolving tablets (ODT) & speedy approvals”

— Bruce F Mackler, Ph.D., J.D.

BETHESDA, MARYLAND, USA, October 28, 2022 /EINPresswire.com/ — Ethicann Prescribed drugs Inc., a Canadian/US specialty pharmaceutical firm, was awarded first place within the Impression class competitors on the Bend Enterprise Convention, hosted by EDCO, which was held on Oct. 20-21, 2022. The Bend Enterprise Convention is the most important Angel Convention within the Pacific Northwest. Ethicann was chosen the winner from amongst 8 entrepreneurial corporations competing within the Impression class, acquired an funding prize of $60,000.

Ethicann Prescribed drugs is an Rising World Chief Growing Excessive-Worth Cannabinoid-Based mostly Moral Drug Therapies.

Ethicann Prescribed drugs Inc. is a Canadian/US specialty pharmaceutical firm reformulating authorised medicine utilizing the oral dissolving pill (ODT) supply know-how, which supplies a metered drug dose that may be delivered underneath the tongue and dissolves in 3 to six seconds. Ethicann’s first product, EPI-002, accommodates THC:CBD (1:1 ratio) is meant to deal with MS spasticity, which a canine pharmacokinetic PK examine has proven to be comparable in API blood ranges as Sativex®, a GW Pharma/Jazz Pharma, 1:1 THC:CBD, in 50% ethanol impure botanical product sprayed onto the internal cheek tissue. EPI-002 is a freeze-dried, metered oral dissolving pill (ODT), and accommodates no ethanol and needs to be simpler for MS spasticity sufferers to make use of.

Ethicann can be reformulating Epidiolex®, a CBD liquid drug squirted into the mouths of pediatric epilepsy sufferers. Right here additionally a metered freeze-dried CBD Zydis oral dissolving pill, needs to be simpler for these pediatric sufferers to make use of. As well as, Ethicann is making use of the Zydis oral dissolving pill supply system to different indications, resembling, chemotherapeutic-induced nausea and vomiting (CINV) and power most cancers ache.

Enterprise Abstract: Ethicann (Canada/US) is an Rising World Chief Growing Excessive-Worth Cannabinoid-Based mostly Moral Drug Therapies and has positioned itself as a cost-efficient pharmaceutical growth firm, utilizing established multinational companions to supply ultra-purified Energetic Pharmaceutical Components (APIs) and the proprietary sublingual Zydis orally disintegrating pill (ODT) know-how. Ethicann is leveraging these partnerships to formulate and additional develop cannabinoid-based pharmaceutical drug merchandise and keep away from deploying capital in constructing and totally staffing its personal services. This enterprise reformulation technique coupled with the usage of abbreviated regulatory approval pathways in varied nations can even be used for speedy growth of its Zydis-based pipeline medicine to deal with different medical indications.

Ahead-looking statements:

Info on this information launch that isn’t present or historic factual data might represent forward-looking data throughout the that means of securities legal guidelines. Implicit on this data, notably in respect of the longer term outlook of Ethicann Prescribed drugs, Inc. (Ethicann) and anticipated occasions or outcomes, are assumptions primarily based on beliefs of Ethicann’s senior administration in addition to data presently obtainable to it. Whereas these assumptions had been thought-about affordable by Ethicann on the time of preparation, they could show to be incorrect. Readers are cautioned that precise outcomes are topic to a lot of dangers and uncertainties, together with the supply of funds and sources to pursue R&D tasks, the profitable and well timed completion of medical research, the power of Ethicann to benefit from enterprise alternatives within the biomedical business, the granting of obligatory approvals by regulatory authorities, normal financial, market and enterprise circumstances, in addition to different dangers and uncertainties. Ethicann doesn’t undertake any obligation to replace forward-looking statements ought to these assumptions change. Nothing on this doc needs to be construed as both a suggestion to promote or a solicitation to purchase or promote Ethicann securities.

Contact:

Bruce F. Mackler

Chairman of the Board

Ethicann Pharmaceutical Inc.

+1 301-529-6984

e-mail: bmackler@ethicannpharma.us

web site: www.ethicann-pharma.com

Bruce F Mackler
Ethicann Pharmaceutical Inc.
+1 301-529-6984
e-mail us right here